Methylphenidate use in geriatric depression: A systematic review

@article{Smith2021MethylphenidateUI,
  title={Methylphenidate use in geriatric depression: A systematic review},
  author={Kristin R Smith and Christie H Kahlon and Jamie N. Brown and Rachel B. Britt},
  journal={International Journal of Geriatric Psychiatry},
  year={2021},
  volume={36},
  pages={1304 - 1312}
}
Geriatric depression is common and is often associated with coexisting medical illnesses, cognitive dysfunction, or both. Treatment with pharmacotherapy is usually required, and many patients may not respond to initial therapy. Thus, there is a need for adjunctive treatment options. The objective of this systematic review is to assess the efficacy and safety of methylphenidate (MPH) in the treatment of geriatric depression. 

Pathomechanisms of Vascular Depression in Older Adults

  • K. Jellinger
  • Psychology, Medicine
    International journal of molecular sciences
  • 2021
Evidence suggests that a variety of vascular mechanisms, in particular cerebral small vessel disease, generalized microvascular, and endothelial dysfunction, as well as metabolic risk factors, may contribute to the development of late-life depression.

Association of Cerebral Small Vessel Disease With Gait and Balance Disorders

The correlation between different imaging features of sporadic CSVD and gait and balance disorders has been reviewed as follows, which can provide beneficial help for standardized management of CSVD.

References

SHOWING 1-10 OF 24 REFERENCES

Methylphenidate: its pharmacology and uses.

The current understanding of the mechanism of action and efficacy of methylphenidate in various clinical conditions is reviewed.

Methylphenidate augmentation of citalopram in elderly depressed patients.

  • H. LavretskyA. Kumar
  • Medicine, Psychology
    The American journal of geriatric psychiatry : official journal of the American Association for Geriatric Psychiatry
  • 2001
Preliminary observations suggest that a combination of MPH and citalopram may be an effective, relatively well tolerated treatment in this patient population and may accelerate onset of action, however, patients may require dosage adjustment for tolerability of this combination.

Citalopram, methylphenidate, or their combination in geriatric depression: a randomized, double-blind, placebo-controlled trial.

Combined treatment with citalopram and methylphenidate demonstrated an enhanced clinical response profile in mood and well-being, as well as a higher rate of remission, compared with either drug alone.

Combined treatment with methylphenidate and citalopram for accelerated response in the elderly: an open trial.

Methylphenidate augmentation of citalopram may be a safe and viable strategy for accelerating antidepressant response in elderly depressed patients and needs to be confirmed in a placebo-controlled trial.

Methylphenidate-enhanced antidepressant response to citalopram in the elderly: a double-blind, placebo-controlled pilot trial.

Combined treatment with citalopram and methylphenidate appears to be a viable strategy for accelerating and enhancing antidepressant response in elderly depressed patients limited by tolerability and safety.

Canadian Network for Mood and Anxiety Treatments (CANMAT) 2016 Clinical Guidelines for the Management of Adults with Major Depressive Disorder

Despite the limited evidence base, extant data and clinical experience suggest that each of these special populations can benefit from the systematic application of treatment guidelines for treatment of MDD.

Clinical Practice Guidelines for Management of Depression in Elderly

Although the incidence of depression among elderly is similar to that reported in adult population, depression in elderly is associated with higher risk of suicide, more frequent hospitalization, higher number of consultations with the treatment agencies and family burden.

The use of Ritalin in psychotherapy of depressions of the aged

  • A. Jacobson
  • Psychology, Medicine
    Psychiatric Quarterly
  • 2005
Ritalin appeared to increase the effectiveness of psychotherapy with elderly depressed patients, and the absence of depressive let-down as the effects of the drug wore off.

Pilot study of augmentation with aripiprazole for incomplete response in late-life depression: getting to remission.

In older adults with MDD with incomplete response to SSRI and SNRI pharmacotherapy, aripiprazole was well tolerated, and symptoms of depression improved significantly during treatment with aripIPrazole.